Toppgene analysis for Wikipedia protein communities, toppgene analysis, cc78_6, positive side

Go To Start Page
Input Parameters [Show Detail]
Training Results [Expand All] [Download All] [Sparse Matrix]
Display pValues and Scores as Table row limit

1: GO: Molecular Function [Display Chart] 6 input genes in category / 55 annotations before applied cutoff / 18661 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 GO:0001042 RNA polymerase I core binding 6.430E-4 2.652E-2
1.218E-1
 3.536E-2 1 2
2 GO:0001075 transcription factor activity, RNA polymerase II core promoter sequence-specific binding involved in preinitiation complex assembly 9.643E-4 2.652E-2
1.218E-1
5.304E-2
 1 3
3 GO:0043125 ErbB-3 class receptor binding 1.607E-3 2.827E-2
1.299E-1
8.837E-2
 1 5
4 GO:0008821 crossover junction endodeoxyribonuclease activity 2.570E-3 2.827E-2
1.299E-1
1.413E-1
 1 8
5 GO:0000150 recombinase activity 2.570E-3 2.827E-2
1.299E-1
1.413E-1
 1 8
6 GO:0016889 endodeoxyribonuclease activity, producing 3'-phosphomonoesters 3.211E-3 2.944E-2
1.352E-1
1.766E-1
 1 10
7 GO:0019864 IgG binding 3.853E-3 2.988E-2
1.373E-1
2.119E-1
 1 12
8 GO:0000983 transcription factor activity, RNA polymerase II core promoter sequence-specific DNA binding 4.494E-3 2.988E-2
1.373E-1
2.471E-1
 1 14
9 GO:0000400 four-way junction DNA binding 5.134E-3 2.988E-2
1.373E-1
2.824E-1
 1 16
10 GO:0000982 transcription factor activity, RNA polymerase II proximal promoter sequence-specific DNA binding 5.433E-3 2.988E-2
1.373E-1
2.988E-1
 2 365
11 GO:0016894 endonuclease activity, active with either ribo- or deoxyribonucleic acids and producing 3'-phosphomonoesters 6.414E-3 3.148E-2
1.446E-1
3.528E-1
 1 20
12 GO:0043175 RNA polymerase core enzyme binding 7.373E-3 3.148E-2
1.446E-1
4.055E-1
 1 23
13 GO:0019865 immunoglobulin binding 7.693E-3 3.148E-2
1.446E-1
4.231E-1
 1 24
14 GO:0000217 DNA secondary structure binding 8.012E-3 3.148E-2
1.446E-1
4.407E-1
 1 25
15 GO:0051879 Hsp90 protein binding 1.152E-2 3.618E-2
1.662E-1
6.336E-1
 1 36
16 GO:0004190 aspartic-type endopeptidase activity 1.152E-2 3.618E-2
1.662E-1
6.336E-1
 1 36
17 GO:0070001 aspartic-type peptidase activity 1.184E-2 3.618E-2
1.662E-1
6.512E-1
 1 37
18 GO:0070063 RNA polymerase binding 1.184E-2 3.618E-2
1.662E-1
6.512E-1
 1 37
19 GO:0098531 transcription factor activity, direct ligand regulated sequence-specific DNA binding 1.597E-2 4.392E-2
2.018E-1
8.784E-1
 1 50
20 GO:0004879 nuclear receptor activity 1.597E-2 4.392E-2
2.018E-1
8.784E-1
 1 50
21 GO:0003707 steroid hormone receptor activity 1.882E-2 4.930E-2
2.265E-1
1.000E0
 1 59
22 GO:0046934 phosphatidylinositol-4,5-bisphosphate 3-kinase activity 1.977E-2 4.943E-2
2.271E-1
1.000E0
 1 62
Show 17 more annotations

2: GO: Biological Process [Display Chart] 6 input genes in category / 443 annotations before applied cutoff / 18623 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 GO:0045137 development of primary sexual characteristics 4.980E-5 1.010E-2
6.741E-2
 2.206E-2 3 256
2 GO:0007548 sex differentiation 8.719E-5 1.010E-2
6.741E-2
 3.862E-2 3 309
3 GO:0050678 regulation of epithelial cell proliferation 9.945E-5 1.010E-2
6.741E-2
 4.406E-2 3 323
4 GO:0050673 epithelial cell proliferation 1.752E-4 1.010E-2
6.741E-2
7.763E-2
 3 391
5 GO:0072258 metanephric interstitial fibroblast differentiation 3.222E-4 1.010E-2
6.741E-2
1.427E-1
 1 1
6 GO:0072165 anterior mesonephric tubule development 3.222E-4 1.010E-2
6.741E-2
1.427E-1
 1 1
7 GO:0072169 specification of posterior mesonephric tubule identity 3.222E-4 1.010E-2
6.741E-2
1.427E-1
 1 1
8 GO:0072184 renal vesicle progenitor cell differentiation 3.222E-4 1.010E-2
6.741E-2
1.427E-1
 1 1
9 GO:1904708 regulation of granulosa cell apoptotic process 3.222E-4 1.010E-2
6.741E-2
1.427E-1
 1 1
10 GO:0072168 specification of anterior mesonephric tubule identity 3.222E-4 1.010E-2
6.741E-2
1.427E-1
 1 1
11 GO:1904709 negative regulation of granulosa cell apoptotic process 3.222E-4 1.010E-2
6.741E-2
1.427E-1
 1 1
12 GO:0072259 metanephric interstitial fibroblast development 3.222E-4 1.010E-2
6.741E-2
1.427E-1
 1 1
13 GO:1904700 granulosa cell apoptotic process 3.222E-4 1.010E-2
6.741E-2
1.427E-1
 1 1
14 GO:0072167 specification of mesonephric tubule identity 3.222E-4 1.010E-2
6.741E-2
1.427E-1
 1 1
15 GO:0051705 multi-organism behavior 3.421E-4 1.010E-2
6.741E-2
1.516E-1
 2 90
16 GO:0090094 metanephric cap mesenchymal cell proliferation involved in metanephros development 6.443E-4 1.142E-2
7.617E-2
2.854E-1
 1 2
17 GO:0048389 intermediate mesoderm development 6.443E-4 1.142E-2
7.617E-2
2.854E-1
 1 2
18 GO:0072185 metanephric cap development 6.443E-4 1.142E-2
7.617E-2
2.854E-1
 1 2
19 GO:2000697 negative regulation of epithelial cell differentiation involved in kidney development 6.443E-4 1.142E-2
7.617E-2
2.854E-1
 1 2
20 GO:0072098 anterior/posterior pattern specification involved in kidney development 6.443E-4 1.142E-2
7.617E-2
2.854E-1
 1 2
21 GO:0061227 pattern specification involved in mesonephros development 6.443E-4 1.142E-2
7.617E-2
2.854E-1
 1 2
22 GO:0072186 metanephric cap morphogenesis 6.443E-4 1.142E-2
7.617E-2
2.854E-1
 1 2
23 GO:0072183 negative regulation of nephron tubule epithelial cell differentiation 6.443E-4 1.142E-2
7.617E-2
2.854E-1
 1 2
24 GO:0072166 posterior mesonephric tubule development 6.443E-4 1.142E-2
7.617E-2
2.854E-1
 1 2
25 GO:0072208 metanephric smooth muscle tissue development 6.443E-4 1.142E-2
7.617E-2
2.854E-1
 1 2
26 GO:0046545 development of primary female sexual characteristics 7.231E-4 1.232E-2
8.220E-2
3.203E-1
 2 131
27 GO:0042698 ovulation cycle 8.019E-4 1.316E-2
8.779E-2
3.553E-1
 2 138
28 GO:0046660 female sex differentiation 8.969E-4 1.338E-2
8.925E-2
3.973E-1
 2 146
29 GO:0060748 tertiary branching involved in mammary gland duct morphogenesis 9.663E-4 1.338E-2
8.925E-2
4.281E-1
 1 3
30 GO:0036023 embryonic skeletal limb joint morphogenesis 9.663E-4 1.338E-2
8.925E-2
4.281E-1
 1 3
31 GO:0036022 limb joint morphogenesis 9.663E-4 1.338E-2
8.925E-2
4.281E-1
 1 3
32 GO:0072190 ureter urothelium development 9.663E-4 1.338E-2
8.925E-2
4.281E-1
 1 3
33 GO:0050679 positive regulation of epithelial cell proliferation 1.285E-3 1.392E-2
9.287E-2
5.691E-1
 2 175
34 GO:0006367 transcription initiation from RNA polymerase II promoter 1.285E-3 1.392E-2
9.287E-2
5.691E-1
 2 175
35 GO:0072180 mesonephric duct morphogenesis 1.288E-3 1.392E-2
9.287E-2
5.707E-1
 1 4
36 GO:0072133 metanephric mesenchyme morphogenesis 1.288E-3 1.392E-2
9.287E-2
5.707E-1
 1 4
37 GO:0072268 pattern specification involved in metanephros development 1.288E-3 1.392E-2
9.287E-2
5.707E-1
 1 4
38 GO:0072194 kidney smooth muscle tissue development 1.288E-3 1.392E-2
9.287E-2
5.707E-1
 1 4
39 GO:0007066 female meiosis sister chromatid cohesion 1.288E-3 1.392E-2
9.287E-2
5.707E-1
 1 4
40 GO:0072131 kidney mesenchyme morphogenesis 1.288E-3 1.392E-2
9.287E-2
5.707E-1
 1 4
41 GO:0060244 negative regulation of cell proliferation involved in contact inhibition 1.288E-3 1.392E-2
9.287E-2
5.707E-1
 1 4
42 GO:0072047 proximal/distal pattern formation involved in nephron development 1.610E-3 1.551E-2
1.035E-1
7.133E-1
 1 5
43 GO:0033088 negative regulation of immature T cell proliferation in thymus 1.610E-3 1.551E-2
1.035E-1
7.133E-1
 1 5
44 GO:0072162 metanephric mesenchymal cell differentiation 1.610E-3 1.551E-2
1.035E-1
7.133E-1
 1 5
45 GO:0072081 specification of nephron tubule identity 1.610E-3 1.551E-2
1.035E-1
7.133E-1
 1 5
46 GO:0038001 paracrine signaling 1.610E-3 1.551E-2
1.035E-1
7.133E-1
 1 5
47 GO:0071897 DNA biosynthetic process 1.860E-3 1.678E-2
1.120E-1
8.239E-1
 2 211
48 GO:0060745 mammary gland branching involved in pregnancy 1.932E-3 1.678E-2
1.120E-1
8.558E-1
 1 6
49 GO:0072143 mesangial cell development 1.932E-3 1.678E-2
1.120E-1
8.558E-1
 1 6
50 GO:0050847 progesterone receptor signaling pathway 1.932E-3 1.678E-2
1.120E-1
8.558E-1
 1 6
Show 45 more annotations

3: GO: Cellular Component [Display Chart] 6 input genes in category / 34 annotations before applied cutoff / 19061 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 GO:0033065 Rad51C-XRCC3 complex 6.295E-4 1.497E-2
6.166E-2
 2.140E-2 1 2
2 GO:0048476 Holliday junction resolvase complex 1.573E-3 1.497E-2
6.166E-2
5.348E-2
 1 5
3 GO:0033063 Rad51B-Rad51C-Rad51D-XRCC2 complex 1.573E-3 1.497E-2
6.166E-2
5.348E-2
 1 5
4 GO:0043219 lateral loop 2.202E-3 1.497E-2
6.166E-2
7.486E-2
 1 7
5 GO:0033061 DNA recombinase mediator complex 2.202E-3 1.497E-2
6.166E-2
7.486E-2
 1 7
6 GO:0016324 apical plasma membrane 4.409E-3 2.498E-2
1.029E-1
1.499E-1
 2 335
7 GO:0045177 apical part of cell 7.107E-3 3.315E-2
1.365E-1
2.416E-1
 2 428
8 GO:0098794 postsynapse 7.799E-3 3.315E-2
1.365E-1
2.652E-1
 2 449
Show 3 more annotations

4: Human Phenotype [Display Chart] 3 input genes in category / 421 annotations before applied cutoff / 4707 genes in category

No results to display

5: Mouse Phenotype [Display Chart] 6 input genes in category / 441 annotations before applied cutoff / 10355 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 MP:0011818 abnormal pancreatic beta cell proliferation 1.651E-4 2.530E-2
1.687E-1
7.280E-2
 2 35
2 MP:0009505 abnormal mammary gland lobule morphology 2.161E-4 2.530E-2
1.687E-1
9.531E-2
 2 40
3 MP:0001134 absent corpus luteum 5.551E-4 2.530E-2
1.687E-1
2.448E-1
 2 64
4 MP:0001126 abnormal ovary morphology 5.762E-4 2.530E-2
1.687E-1
2.541E-1
 3 326
5 MP:0000992 absent primary muscle spindle 5.794E-4 2.530E-2
1.687E-1
2.555E-1
 1 1
6 MP:0000996 partial loss of secondary muscle spindle 5.794E-4 2.530E-2
1.687E-1
2.555E-1
 1 1
7 MP:0000991 abnormal primary muscle spindle morphology 5.794E-4 2.530E-2
1.687E-1
2.555E-1
 1 1
8 MP:0000994 abnormal secondary muscle spindle morphology 5.794E-4 2.530E-2
1.687E-1
2.555E-1
 1 1
9 MP:0009664 abnormal luminal closure 5.794E-4 2.530E-2
1.687E-1
2.555E-1
 1 1
10 MP:0000995 absent secondary muscle spindle 5.794E-4 2.530E-2
1.687E-1
2.555E-1
 1 1
11 MP:0003140 dilated heart atrium 7.024E-4 2.530E-2
1.687E-1
3.098E-1
 2 72
12 MP:0020578 abnormal pancreatic beta cell number 7.620E-4 2.530E-2
1.687E-1
3.360E-1
 2 75
13 MP:0013324 abnormal female reproductive gland morphology 7.833E-4 2.530E-2
1.687E-1
3.455E-1
 3 362
14 MP:0001719 absent vitelline blood vessels 8.030E-4 2.530E-2
1.687E-1
3.541E-1
 2 77
15 MP:0001272 increased metastatic potential 1.001E-3 2.942E-2
1.962E-1
4.413E-1
 2 86
16 MP:0001080 defasiculated phrenic nerve 1.159E-3 3.005E-2
2.004E-1
5.109E-1
 1 2
17 MP:0009663 abnormal uterine-embryonic axis 1.159E-3 3.005E-2
2.004E-1
5.109E-1
 1 2
18 MP:0006107 abnormal fetal atrioventricular canal morphology 1.661E-3 3.193E-2
2.129E-1
7.324E-1
 2 111
19 MP:0002679 abnormal corpus luteum morphology 1.691E-3 3.193E-2
2.129E-1
7.456E-1
 2 112
20 MP:0009170 abnormal pancreatic islet size 1.691E-3 3.193E-2
2.129E-1
7.456E-1
 2 112
21 MP:0011412 gonadal ridge hypoplasia 1.737E-3 3.193E-2
2.129E-1
7.662E-1
 1 3
22 MP:0009353 twin decidual capsule 1.737E-3 3.193E-2
2.129E-1
7.662E-1
 1 3
23 MP:0009662 abnormal uterine receptivity 1.737E-3 3.193E-2
2.129E-1
7.662E-1
 1 3
24 MP:0010986 abnormal mesonephric mesenchyme morphology 1.737E-3 3.193E-2
2.129E-1
7.662E-1
 1 3
25 MP:0009209 abnormal internal female genitalia morphology 1.937E-3 3.417E-2
2.278E-1
8.543E-1
 3 494
26 MP:0009080 uterus inflammation 2.316E-3 3.646E-2
2.431E-1
1.000E0
 1 4
27 MP:0008870 increased mature ovarian follicle number 2.316E-3 3.646E-2
2.431E-1
1.000E0
 1 4
28 MP:0009352 impaired spacing of implantation sites 2.316E-3 3.646E-2
2.431E-1
1.000E0
 1 4
29 MP:0000858 altered metastatic potential 2.815E-3 3.646E-2
2.431E-1
1.000E0
 2 145
30 MP:0004075 decreased Schwann cell precursor number 2.894E-3 3.646E-2
2.431E-1
1.000E0
 1 5
31 MP:0001376 abnormal mating receptivity 2.894E-3 3.646E-2
2.431E-1
1.000E0
 1 5
32 MP:0013590 enlarged thymus medulla 2.894E-3 3.646E-2
2.431E-1
1.000E0
 1 5
33 MP:0009075 rudimentary Wolffian ducts 2.894E-3 3.646E-2
2.431E-1
1.000E0
 1 5
34 MP:0009088 thin uterine horn 2.894E-3 3.646E-2
2.431E-1
1.000E0
 1 5
35 MP:0009091 endometrium hypoplasia 2.894E-3 3.646E-2
2.431E-1
1.000E0
 1 5
36 MP:0005217 abnormal pancreatic beta cell morphology 3.129E-3 3.646E-2
2.431E-1
1.000E0
 2 153
37 MP:0000628 abnormal mammary gland development 3.169E-3 3.646E-2
2.431E-1
1.000E0
 2 154
38 MP:0002676 uterus hyperplasia 3.472E-3 3.646E-2
2.431E-1
1.000E0
 1 6
39 MP:0010039 abnormal trophoblast giant cell proliferation 3.472E-3 3.646E-2
2.431E-1
1.000E0
 1 6
40 MP:0009666 abnormal embryo attachment 3.472E-3 3.646E-2
2.431E-1
1.000E0
 1 6
41 MP:0011387 absent metanephric mesenchyme 3.472E-3 3.646E-2
2.431E-1
1.000E0
 1 6
42 MP:0003190 fused synovial joints 3.472E-3 3.646E-2
2.431E-1
1.000E0
 1 6
43 MP:0004074 abnormal Schwann cell precursor morphology 4.050E-3 3.800E-2
2.534E-1
1.000E0
 1 7
44 MP:0008468 absent muscle spindles 4.050E-3 3.800E-2
2.534E-1
1.000E0
 1 7
45 MP:0002742 enlarged submandibular lymph nodes 4.050E-3 3.800E-2
2.534E-1
1.000E0
 1 7
46 MP:0009627 abnormal submandibular lymph node morphology 4.050E-3 3.800E-2
2.534E-1
1.000E0
 1 7
47 MP:0010987 abnormal nephrogenic mesenchyme morphogenesis 4.050E-3 3.800E-2
2.534E-1
1.000E0
 1 7
48 MP:0009251 enlarged endometrial glands 4.628E-3 3.851E-2
2.567E-1
1.000E0
 1 8
49 MP:0004868 increased endometrial carcinoma incidence 4.628E-3 3.851E-2
2.567E-1
1.000E0
 1 8
50 MP:0013401 increased endometrial gland number 4.628E-3 3.851E-2
2.567E-1
1.000E0
 1 8
Show 45 more annotations

6: Domain [Display Chart] 6 input genes in category / 55 annotations before applied cutoff / 18735 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 PD021604 SV autoAg ProDom 3.203E-4 3.523E-3 1.618E-2 1.761E-2 1 1
2 PF02161 Prog receptor Pfam 3.203E-4 3.523E-3 1.618E-2 1.761E-2 1 1
3 IPR007990 PIP InterPro 3.203E-4 3.523E-3 1.618E-2 1.761E-2 1 1
4 PF05326 SVA Pfam 3.203E-4 3.523E-3 1.618E-2 1.761E-2 1 1
5 IPR000128 Progest rcpt InterPro 3.203E-4 3.523E-3 1.618E-2 1.761E-2 1 1
6 IPR016245 Tyr kinase EGF/ERB/XmrK rcpt InterPro 1.281E-3 5.133E-3 2.358E-2
7.043E-2
 1 4
7 IPR010995 DNA repair Rad51/TF NusA a-hlx InterPro 1.281E-3 5.133E-3 2.358E-2
7.043E-2
 1 4
8 IPR021157 Cyt c1 TM anchor C InterPro 1.600E-3 5.133E-3 2.358E-2
8.802E-2
 1 5
9 IPR032778 GF recep IV InterPro 1.920E-3 5.133E-3 2.358E-2
1.056E-1
 1 6
10 IPR033925 Rad51 DMC1 RadA InterPro 1.920E-3 5.133E-3 2.358E-2
1.056E-1
 1 6
11 IPR016467 DNA recomb/repair RecA-like InterPro 1.920E-3 5.133E-3 2.358E-2
1.056E-1
 1 6
12 PF14843 GF recep IV Pfam 1.920E-3 5.133E-3 2.358E-2
1.056E-1
 1 6
13 3.10.260.20 - Gene3D 2.240E-3 5.133E-3 2.358E-2
1.232E-1
 1 7
14 PF01030 Recep L domain Pfam 2.240E-3 5.133E-3 2.358E-2
1.232E-1
 1 7
15 PF02437 Ski Sno Pfam 2.240E-3 5.133E-3 2.358E-2
1.232E-1
 1 7
16 PF00757 Furin-like Pfam 2.240E-3 5.133E-3 2.358E-2
1.232E-1
 1 7
17 PS50162 RECA 2 PROSITE 2.240E-3 5.133E-3 2.358E-2
1.232E-1
 1 7
18 IPR003380 Transform Ski InterPro 2.240E-3 5.133E-3 2.358E-2
1.232E-1
 1 7
19 IPR020588 RecA ATP-bd InterPro 2.240E-3 5.133E-3 2.358E-2
1.232E-1
 1 7
20 3.80.20.20 - Gene3D 2.240E-3 5.133E-3 2.358E-2
1.232E-1
 1 7
21 IPR006211 Furin-like Cys-rich dom InterPro 2.240E-3 5.133E-3 2.358E-2
1.232E-1
 1 7
22 IPR000494 Rcpt L-dom InterPro 2.240E-3 5.133E-3 2.358E-2
1.232E-1
 1 7
23 PF08423 Rad51 Pfam 2.240E-3 5.133E-3 2.358E-2
1.232E-1
 1 7
24 IPR013632 DNA recomb/repair Rad51 C InterPro 2.240E-3 5.133E-3 2.358E-2
1.232E-1
 1 7
25 IPR009061 DNA-bd dom put InterPro 3.518E-3 7.740E-3 3.555E-2
1.935E-1
 1 11
26 IPR006212 Furin repeat InterPro 5.752E-3 1.172E-2
5.382E-2
3.163E-1
 1 18
27 SM00261 FU SMART 5.752E-3 1.172E-2
5.382E-2
3.163E-1
 1 18
28 IPR001628 Znf hrmn rcpt InterPro 1.464E-2 2.271E-2
1.043E-1
8.054E-1
 1 46
29 IPR001723 Nuclear hrmn rcpt InterPro 1.464E-2 2.271E-2
1.043E-1
8.054E-1
 1 46
30 SM00399 ZnF C4 SMART 1.464E-2 2.271E-2
1.043E-1
8.054E-1
 1 46
31 PS00031 NUCLEAR REC DBD 1 PROSITE 1.464E-2 2.271E-2
1.043E-1
8.054E-1
 1 46
32 PF00105 zf-C4 Pfam 1.464E-2 2.271E-2
1.043E-1
8.054E-1
 1 46
33 PS51030 NUCLEAR REC DBD 2 PROSITE 1.464E-2 2.271E-2
1.043E-1
8.054E-1
 1 46
34 1.10.565.10 - Gene3D 1.496E-2 2.271E-2
1.043E-1
8.228E-1
 1 47
35 IPR000536 Nucl hrmn rcpt lig-bd InterPro 1.528E-2 2.271E-2
1.043E-1
8.402E-1
 1 48
36 SM00430 HOLI SMART 1.528E-2 2.271E-2
1.043E-1
8.402E-1
 1 48
37 PF00104 Hormone recep Pfam 1.528E-2 2.271E-2
1.043E-1
8.402E-1
 1 48
38 3.30.50.10 - Gene3D 1.812E-2 2.600E-2
1.194E-1
9.965E-1
 1 57
39 IPR013088 Znf NHR/GATA InterPro 1.843E-2 2.600E-2
1.194E-1
1.000E0
 1 58
40 SM00219 TyrKc SMART 2.786E-2 3.737E-2
1.717E-1
1.000E0
 1 88
41 IPR020635 Tyr kinase cat dom InterPro 2.786E-2 3.737E-2
1.717E-1
1.000E0
 1 88
42 IPR008266 Tyr kinase AS InterPro 3.067E-2 3.923E-2
1.802E-1
1.000E0
 1 97
43 PS00109 PROTEIN KINASE TYR PROSITE 3.067E-2 3.923E-2
1.802E-1
1.000E0
 1 97
44 IPR014756 Ig E-set InterPro 3.285E-2 4.107E-2
1.886E-1
1.000E0
 1 104
45 PF07714 Pkinase Tyr Pfam 4.061E-2 4.964E-2
2.280E-1
1.000E0
 1 129
Show 40 more annotations

7: Pathway [Display Chart] 4 input genes in category / 114 annotations before applied cutoff / 12450 genes in category

No results to display

8: Pubmed [Display Chart] 6 input genes in category / 4355 annotations before applied cutoff / 38193 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 23723333 Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis. Pubmed 2.057E-8 4.976E-6 4.456E-5 8.957E-5 2 2
2 27377889 An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer. Pubmed 2.057E-8 4.976E-6 4.456E-5 8.957E-5 2 2
3 18629635 Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors. Pubmed 2.057E-8 4.976E-6 4.456E-5 8.957E-5 2 2
4 25778292 Progesterone receptor status in determining the prognosis of estrogen receptor positive/ HER2 negative breast carcinoma patients. Pubmed 2.057E-8 4.976E-6 4.456E-5 8.957E-5 2 2
5 20167054 The relationship of cerb B 2 expression with estrogen receptor and progesterone receptor and prognostic parameters in endometrial carcinomas. Pubmed 2.057E-8 4.976E-6 4.456E-5 8.957E-5 2 2
6 21544804 Serum enterolactone and postmenopausal breast cancer risk by estrogen, progesterone and herceptin 2 receptor status. Pubmed 2.057E-8 4.976E-6 4.456E-5 8.957E-5 2 2
7 23663520 Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15. Pubmed 2.057E-8 4.976E-6 4.456E-5 8.957E-5 2 2
8 19838027 [Clinicopathological features of young patients with triple negative breast cancer]. Pubmed 2.057E-8 4.976E-6 4.456E-5 8.957E-5 2 2
9 20713855 Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis. Pubmed 2.057E-8 4.976E-6 4.456E-5 8.957E-5 2 2
10 26579819 Prognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer. Pubmed 2.057E-8 4.976E-6 4.456E-5 8.957E-5 2 2
11 23757214 Association of estrogen receptor, progesterone receptor and HER2 following neoadjuvant systemic treatment in breast cancer patients undergoing surgery. Pubmed 2.057E-8 4.976E-6 4.456E-5 8.957E-5 2 2
12 28416639 Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen. Pubmed 2.057E-8 4.976E-6 4.456E-5 8.957E-5 2 2
13 21700456 Estrogen receptor positive operable breast cancer: does menopausal status impact on HER2 and progesterone receptor status? Pubmed 2.057E-8 4.976E-6 4.456E-5 8.957E-5 2 2
14 24021827 [The expression assessment of the estrogen, progesterone and HER2 receptors in selected malignant tumors of the salivary glands]. Pubmed 6.170E-8 4.976E-6 4.456E-5 2.687E-4 2 3
15 19208313 Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan. Pubmed 6.170E-8 4.976E-6 4.456E-5 2.687E-4 2 3
16 19574486 Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Pubmed 6.170E-8 4.976E-6 4.456E-5 2.687E-4 2 3
17 18189290 The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004. Pubmed 6.170E-8 4.976E-6 4.456E-5 2.687E-4 2 3
18 20308044 Familial and sporadic breast cancers: differences in clinical, histopathological, and immunohistochemical features. Pubmed 6.170E-8 4.976E-6 4.456E-5 2.687E-4 2 3
19 26550991 DNA Methylation Patterns Can Estimate Nonequivalent Outcomes of Breast Cancer with the Same Receptor Subtypes. Pubmed 6.170E-8 4.976E-6 4.456E-5 2.687E-4 2 3
20 25908555 Defining breast cancer intrinsic subtypes by quantitative receptor expression. Pubmed 6.170E-8 4.976E-6 4.456E-5 2.687E-4 2 3
21 16901007 Glassy cell carcinoma of the cervix: cytologic features and expression of estrogen receptor, progesterone receptor and Her2/neu protein. Pubmed 6.170E-8 4.976E-6 4.456E-5 2.687E-4 2 3
22 25802405 Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis. Pubmed 6.170E-8 4.976E-6 4.456E-5 2.687E-4 2 3
23 25778295 Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer. Pubmed 6.170E-8 4.976E-6 4.456E-5 2.687E-4 2 3
24 20876300 Progesterone receptor induces ErbB-2 nuclear translocation to promote breast cancer growth via a novel transcriptional effect: ErbB-2 function as a coactivator of Stat3. Pubmed 6.170E-8 4.976E-6 4.456E-5 2.687E-4 2 3
25 23397283 The detection of ESR1/PGR/ERBB2 mRNA levels by RT-QPCR: a better approach for subtyping breast cancer and predicting prognosis. Pubmed 6.170E-8 4.976E-6 4.456E-5 2.687E-4 2 3
26 26829108 Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuantâ?¢ Microarray Based Assay. Pubmed 6.170E-8 4.976E-6 4.456E-5 2.687E-4 2 3
27 26742937 Ki-67 is a prognostic marker for hormone receptor positive tumors. Pubmed 6.170E-8 4.976E-6 4.456E-5 2.687E-4 2 3
28 30534815 Assessment of hormonal receptor immunoexpression and Her2 status in invasive breast cancer after conservative and radical surgery. Pubmed 6.170E-8 4.976E-6 4.456E-5 2.687E-4 2 3
29 28975433 Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study. Pubmed 6.170E-8 4.976E-6 4.456E-5 2.687E-4 2 3
30 12937679 Mammary tumors in HER-2/NEU mice are characterized by low content of estrogen receptors-alpha and absence of progesterone receptors. Pubmed 6.170E-8 4.976E-6 4.456E-5 2.687E-4 2 3
31 20920367 Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype. Pubmed 6.170E-8 4.976E-6 4.456E-5 2.687E-4 2 3
32 25338681 Integrative investigation on breast cancer in ER, PR and HER2-defined subgroups using mRNA and miRNA expression profiling. Pubmed 6.170E-8 4.976E-6 4.456E-5 2.687E-4 2 3
33 30117066 Co-expressed genes enhance precision of receptor status identification in breast cancer patients. Pubmed 6.170E-8 4.976E-6 4.456E-5 2.687E-4 2 3
34 21437249 Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers. Pubmed 6.170E-8 4.976E-6 4.456E-5 2.687E-4 2 3
35 22119825 Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein. Pubmed 6.170E-8 4.976E-6 4.456E-5 2.687E-4 2 3
36 16799708 Prevalence of hormone receptors and HER2/neu in breast cancer cases in Jordan. Pubmed 6.170E-8 4.976E-6 4.456E-5 2.687E-4 2 3
37 24162264 The characteristics of breast cancer subtypes: implications for treatment guidelines and individualized treatment strategies in China. Pubmed 6.170E-8 4.976E-6 4.456E-5 2.687E-4 2 3
38 24667714 High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial. Pubmed 6.170E-8 4.976E-6 4.456E-5 2.687E-4 2 3
39 22414972 Factors influencing the hormone receptor and HER2 levels in breast cancer: a population-based analysis. Pubmed 6.170E-8 4.976E-6 4.456E-5 2.687E-4 2 3
40 19887485 Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer. Pubmed 6.170E-8 4.976E-6 4.456E-5 2.687E-4 2 3
41 22022496 Hormone receptor and ERBB2 status in gene expression profiles of human breast tumor samples. Pubmed 6.170E-8 4.976E-6 4.456E-5 2.687E-4 2 3
42 27022068 Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial. Pubmed 6.170E-8 4.976E-6 4.456E-5 2.687E-4 2 3
43 21029696 [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy]. Pubmed 6.170E-8 4.976E-6 4.456E-5 2.687E-4 2 3
44 23818347 Evaluation of changes in biologic markers ER, PR, HER 2 and Ki-67 index in breast cancer with administration of neoadjuvant dose dense doxorubicin, cyclophosphamide followed by paclitaxel chemotherapy. Pubmed 6.170E-8 4.976E-6 4.456E-5 2.687E-4 2 3
45 26403396 CORRELATION BETWEEN CLINICAL PATHOLOGY OF LUMINAL B BREAST CANCER AND DETERMINATION OF ESTROGEN RECEPTOR, PROGESTERONE RECEPTOR AND HER2 EXPRESSION COMBINED WITH NUCLEAR MORPHOLOGY. Pubmed 6.170E-8 4.976E-6 4.456E-5 2.687E-4 2 3
46 20557310 Comparison of core needle biopsy (CNB) and surgical specimens for accurate preoperative evaluation of ER, PgR and HER2 status of breast cancer patients. Pubmed 6.170E-8 4.976E-6 4.456E-5 2.687E-4 2 3
47 28870906 Discordance and Conversion Rates of Progesterone-, Estrogen-, and HER2/neu-Receptor Status in Primary Breast Cancer and Brain Metastasis Mainly Triggered by Hormone Therapy. Pubmed 6.170E-8 4.976E-6 4.456E-5 2.687E-4 2 3
48 16168103 Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan. Pubmed 6.170E-8 4.976E-6 4.456E-5 2.687E-4 2 3
49 20436503 Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer. Pubmed 6.170E-8 4.976E-6 4.456E-5 2.687E-4 2 3
50 20873988 The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features. Pubmed 6.170E-8 4.976E-6 4.456E-5 2.687E-4 2 3
Show 45 more annotations

9: Interaction [Display Chart] 6 input genes in category / 390 annotations before applied cutoff / 17703 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 int:NCOR1 NCOR1 interactions 2.377E-5 9.269E-3
6.066E-2
 9.269E-3 3 190
2 int:TGFBR2 TGFBR2 interactions 5.049E-4 3.945E-2
2.582E-1
1.969E-1
 2 104
3 int:MUC4 MUC4 interactions 1.016E-3 3.945E-2
2.582E-1
3.964E-1
 1 3
4 int:CCDC140 CCDC140 interactions 1.016E-3 3.945E-2
2.582E-1
3.964E-1
 1 3
5 int:STK11 STK11 interactions 1.060E-3 3.945E-2
2.582E-1
4.134E-1
 2 151
6 int:NCOA3 NCOA3 interactions 1.074E-3 3.945E-2
2.582E-1
4.189E-1
 2 152
7 int:SH2D5 SH2D5 interactions 1.355E-3 3.945E-2
2.582E-1
5.285E-1
 1 4
8 int:KLF9 KLF9 interactions 1.694E-3 3.945E-2
2.582E-1
6.605E-1
 1 5
9 int:CLCN6 CLCN6 interactions 1.694E-3 3.945E-2
2.582E-1
6.605E-1
 1 5
10 int:MMP16 MMP16 interactions 1.694E-3 3.945E-2
2.582E-1
6.605E-1
 1 5
11 int:DOK6 DOK6 interactions 2.032E-3 3.945E-2
2.582E-1
7.925E-1
 1 6
12 int:TTC9B TTC9B interactions 2.032E-3 3.945E-2
2.582E-1
7.925E-1
 1 6
13 int:OSR1 OSR1 interactions 2.370E-3 3.945E-2
2.582E-1
9.245E-1
 1 7
14 int:DACH2 DACH2 interactions 2.709E-3 3.945E-2
2.582E-1
1.000E0
 1 8
15 int:GMPR2 GMPR2 interactions 2.709E-3 3.945E-2
2.582E-1
1.000E0
 1 8
16 int:HPSE HPSE interactions 2.709E-3 3.945E-2
2.582E-1
1.000E0
 1 8
17 int:TCF3 TCF3 interactions 2.758E-3 3.945E-2
2.582E-1
1.000E0
 2 245
18 int:NF2 NF2 interactions 3.007E-3 3.945E-2
2.582E-1
1.000E0
 2 256
19 int:UBE3A UBE3A interactions 3.030E-3 3.945E-2
2.582E-1
1.000E0
 2 257
20 int:SLA2 SLA2 interactions 3.047E-3 3.945E-2
2.582E-1
1.000E0
 1 9
21 int:SH2D3A SH2D3A interactions 3.047E-3 3.945E-2
2.582E-1
1.000E0
 1 9
22 int:PTPRT PTPRT interactions 3.047E-3 3.945E-2
2.582E-1
1.000E0
 1 9
23 int:HENMT1 HENMT1 interactions 3.385E-3 3.945E-2
2.582E-1
1.000E0
 1 10
24 int:MPZL2 MPZL2 interactions 3.385E-3 3.945E-2
2.582E-1
1.000E0
 1 10
25 int:ABCB5 ABCB5 interactions 3.723E-3 3.945E-2
2.582E-1
1.000E0
 1 11
26 int:SH3BGRL3 SH3BGRL3 interactions 3.723E-3 3.945E-2
2.582E-1
1.000E0
 1 11
27 int:BTC BTC interactions 3.723E-3 3.945E-2
2.582E-1
1.000E0
 1 11
28 int:ZNF280C ZNF280C interactions 3.723E-3 3.945E-2
2.582E-1
1.000E0
 1 11
29 int:SWSAP1 SWSAP1 interactions 3.723E-3 3.945E-2
2.582E-1
1.000E0
 1 11
30 int:HELQ HELQ interactions 4.061E-3 3.945E-2
2.582E-1
1.000E0
 1 12
31 int:OSMR OSMR interactions 4.061E-3 3.945E-2
2.582E-1
1.000E0
 1 12
32 int:STAT3 STAT3 interactions 4.158E-3 3.945E-2
2.582E-1
1.000E0
 2 302
33 int:TCEAL2 TCEAL2 interactions 4.399E-3 3.945E-2
2.582E-1
1.000E0
 1 13
34 int:RIN2 RIN2 interactions 4.399E-3 3.945E-2
2.582E-1
1.000E0
 1 13
35 int:SH2B3 SH2B3 interactions 4.399E-3 3.945E-2
2.582E-1
1.000E0
 1 13
36 int:STUB1 STUB1 interactions 4.432E-3 3.945E-2
2.582E-1
1.000E0
 2 312
37 int:PHF23 PHF23 interactions 4.736E-3 3.945E-2
2.582E-1
1.000E0
 1 14
38 int:DTWD2 DTWD2 interactions 4.736E-3 3.945E-2
2.582E-1
1.000E0
 1 14
39 int:TXK TXK interactions 4.736E-3 3.945E-2
2.582E-1
1.000E0
 1 14
40 int:SH2D1B SH2D1B interactions 4.736E-3 3.945E-2
2.582E-1
1.000E0
 1 14
41 int:PRDM2 PRDM2 interactions 4.736E-3 3.945E-2
2.582E-1
1.000E0
 1 14
42 int:OPCML OPCML interactions 5.074E-3 3.945E-2
2.582E-1
1.000E0
 1 15
43 int:ANKS1B ANKS1B interactions 5.074E-3 3.945E-2
2.582E-1
1.000E0
 1 15
44 int:TTYH2 TTYH2 interactions 5.074E-3 3.945E-2
2.582E-1
1.000E0
 1 15
45 int:SOX3 SOX3 interactions 5.074E-3 3.945E-2
2.582E-1
1.000E0
 1 15
46 int:SHC2 SHC2 interactions 5.411E-3 3.945E-2
2.582E-1
1.000E0
 1 16
47 int:CHN1 CHN1 interactions 5.411E-3 3.945E-2
2.582E-1
1.000E0
 1 16
48 int:PTDSS1 PTDSS1 interactions 5.411E-3 3.945E-2
2.582E-1
1.000E0
 1 16
49 int:GLCE GLCE interactions 5.749E-3 3.945E-2
2.582E-1
1.000E0
 1 17
50 int:SH3BGRL SH3BGRL interactions 5.749E-3 3.945E-2
2.582E-1
1.000E0
 1 17
Show 45 more annotations

10: Cytoband [Display Chart] 6 input genes in category / 6 annotations before applied cutoff / 34661 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 11q22-q23 11q22-q23 1.038E-3 5.708E-3 1.399E-2 6.230E-3 1 6
2 13q22 13q22 1.903E-3 5.708E-3 1.399E-2 1.142E-2 1 11
3 2p24.1 2p24.1 4.148E-3 8.295E-3 2.032E-2 2.489E-2 1 24
4 17q25.1 17q25.1 1.428E-2 2.142E-2
5.249E-2
8.570E-2
 1 83
5 17q12 17q12 1.804E-2 2.165E-2
5.304E-2
1.082E-1
 1 105
6 7q34 7q34 2.958E-2 2.958E-2
7.247E-2
1.775E-1
 1 173
Show 1 more annotation

11: Transcription Factor Binding Site [Display Chart] 5 input genes in category / 56 annotations before applied cutoff / 9770 genes in category

No results to display

12: Gene Family [Display Chart] 4 input genes in category / 5 annotations before applied cutoff / 18194 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 1096 Erb-b2 receptor tyrosine kinases genenames.org 8.792E-4 4.396E-3 1.004E-2 4.396E-3 1 4
2 548 Fanconi anemia complementation groups genenames.org 4.390E-3 1.098E-2 2.506E-2 2.195E-2 1 20
3 71 Nuclear hormone receptors genenames.org 1.073E-2 1.396E-2 3.187E-2
5.365E-2
 1 49
4 870 Minor histocompatibility antigens|FERM domain containing genenames.org 1.117E-2 1.396E-2 3.187E-2
5.583E-2
 1 51

13: Coexpression [Display Chart] 6 input genes in category / 633 annotations before applied cutoff / 23137 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 19266279-TableA Human Breast Chen09 20genes GeneSigDB 3.362E-7 2.128E-4 1.496E-3 2.128E-4 2 4
2 16491124-SuppTable1 Human Breast Doane06 145genes GeneSigDB 1.648E-6 3.648E-4 2.564E-3 1.043E-3 3 102
3 M19439 Genes up-regulated in breast cancer samples positive for ESR1 [GeneID=2099] compared to the ESR1 negative tumors. MSigDB C2: CGP Curated Gene Sets (v6.0) 2.185E-6 3.648E-4 2.564E-3 1.383E-3 3 112
4 M737 Genes down-regulated between two breast carcinoma subtypes: metaplastic (MCB) and ductal (DCB). MSigDB C2: CGP Curated Gene Sets (v6.0) 2.305E-6 3.648E-4 2.564E-3 1.459E-3 3 114
5 19723662-SupplTable2 Human Breast Culhane09 12genes MolecularSubtype GeneSigDB 3.695E-6 4.515E-4 3.173E-3 2.339E-3 2 12
6 19204204-SupplementaryTable4 Human Breast Parker09 161genes IntrinsicGenes RTPCR GeneSigDB 4.279E-6 4.515E-4 3.173E-3 2.709E-3 3 140
7 17603561-STable1 Human Breast Lien07 213genes GeneSigDB 9.566E-6 8.651E-4 6.080E-3 6.055E-3 3 183
8 15591335-GeneList Human Breast Paik04 21genes GeneSigDB 1.174E-5 9.292E-4 6.531E-3 7.434E-3 2 21
9 15374954-Table1 Human Breast Orsetti04 39genes GeneSigDB 1.543E-5 1.085E-3 7.627E-3 9.766E-3 2 24
10 15606925-Table3 Human Breast Bieche04 47genes GeneSigDB 5.771E-5 3.458E-3 2.430E-2 3.653E-2 2 46
11 19204204-SupplementaryTable8 Human Breast Parker09 50genes IntrinsicGenes PAM50 GeneSigDB 6.288E-5 3.458E-3 2.430E-2 3.980E-2 2 48
12 15150092-Table2 Human StemCell Medjkane04 51genes GeneSigDB 6.555E-5 3.458E-3 2.430E-2 4.149E-2 2 49
13 16626501-Suppl2 Human Breast Perreard06 53genes RT-PCR Molecular Subtype Intrisinc Genes GeneSigDB 7.105E-5 3.460E-3 2.432E-2 4.498E-2 2 51
14 17850661-TableS4 Human Breast Yau07 103genes GeneSigDB 1.626E-4 7.351E-3
5.166E-2
1.029E-1
 2 77
15 M5549 Genes up-regulated in lobular carcinoma vs normal lobular breast cells. MSigDB C2: CGP Curated Gene Sets (v6.0) 2.424E-4 1.023E-2
7.189E-2
1.534E-1
 2 94
16 15899800-TableS1 Human Breast Martens05 117genes GeneSigDB 3.689E-4 1.460E-2
1.026E-1
2.335E-1
 2 116
17 M3102 Genes up-regulated in the erbb2 subype of breast cancer samples, characterized by higher expression of ERBB2 [GeneID=2064]. MSigDB C2: CGP Curated Gene Sets (v6.0) 5.834E-4 2.172E-2
1.527E-1
3.693E-1
 2 146
18 17683518-193GeneTable Human Breast Teschendorff07 193genes Erpos GeneSigDB 7.804E-4 2.464E-2
1.732E-1
4.940E-1
 2 169
19 17389037-Tab6 Human Breast Turashvili07 208genes GeneSigDB 7.989E-4 2.464E-2
1.732E-1
5.057E-1
 2 171
20 16536878-SuppTable2 Human Breast Muggerud06 232genes GeneSigDB 8.269E-4 2.464E-2
1.732E-1
5.234E-1
 2 174
21 M8345 Genes down-regulated in activated versus induced T reg cells. MSigDB C7: Immunologic Signatures (v6.0) 1.047E-3 2.464E-2
1.732E-1
6.629E-1
 2 196
22 M7238 Genes up-regulated in cortical thymocytes versus thymus whole cortex. MSigDB C7: Immunologic Signatures (v6.0) 1.058E-3 2.464E-2
1.732E-1
6.696E-1
 2 197
23 M9941 Genes down-regulated in B lymphocytes: wildtype versus MAP3K7 [GeneID=6885]. MSigDB C7: Immunologic Signatures (v6.0) 1.069E-3 2.464E-2
1.732E-1
6.764E-1
 2 198
24 M3706 Genes down-regulated in comparison of control dendritic cells (DC) at 0 h versus those stimulated with poly(I:C) (TLR3 agonist) at 0.5 h. MSigDB C7: Immunologic Signatures (v6.0) 1.090E-3 2.464E-2
1.732E-1
6.900E-1
 2 200
25 M7505 Genes down-regulated in CD4 [GeneID=920] T cells: non-Tfh versus Tfh (T follicular helper) from germinal center. MSigDB C7: Immunologic Signatures (v6.0) 1.090E-3 2.464E-2
1.732E-1
6.900E-1
 2 200
26 M5596 Genes up-regulated in comparison of NK cells versus Th2 cells. MSigDB C7: Immunologic Signatures (v6.0) 1.090E-3 2.464E-2
1.732E-1
6.900E-1
 2 200
27 M5233 Genes up-regulated in comparison of macrophages exposed to L. donovani versus macrophages exposed to T. gondii. MSigDB C7: Immunologic Signatures (v6.0) 1.090E-3 2.464E-2
1.732E-1
6.900E-1
 2 200
28 M3847 Genes down-regulated in comparison of dendritic cells (DC) stimulated with poly(I:C) (TLR3 agonist) at 24 h versus DC cells stimulated with Pam3Csk4 (TLR1/2 agonist) at 24 h. MSigDB C7: Immunologic Signatures (v6.0) 1.090E-3 2.464E-2
1.732E-1
6.900E-1
 2 200
29 20479250-TableS4 Human Breast Loi10 278genes GeneSigDB 1.438E-3 3.138E-2
2.205E-1
9.100E-1
 2 230
30 M10196 The 'ER-alpha profile': genes down-regulated in T47D cells (breast cancer, ESR2 [GeneID=2100] Tet-Off) upon activation of ESR1 [GeneID=2099] by estradiol (E2) [PubChem=5757]. MSigDB C2: CGP Curated Gene Sets (v6.0) 1.555E-3 3.281E-2
2.306E-1
9.844E-1
 1 6
31 16536878-SuppTable1 Human Breast Muggerud06 271genes GeneSigDB 1.735E-3 3.377E-2
2.374E-1
1.000E0
 2 253
32 19261849-TableS5 Human Endometrial Salvesen09 11genes Correlations GeneSigDB 1.814E-3 3.377E-2
2.374E-1
1.000E0
 1 7
33 M7081 Cluster 8: selected ERBB2 [GeneID=2064] amplicon genes clustered together across breast cancer samples. MSigDB C2: CGP Curated Gene Sets (v6.0) 1.814E-3 3.377E-2
2.374E-1
1.000E0
 1 7
34 19261849-TableS4a Human Endometrial Salvesen09 11genes PeakRegions GeneSigDB 1.814E-3 3.377E-2
2.374E-1
1.000E0
 1 7
35 M19387 Genes significantly mutated in 91 glioblastoma samples. MSigDB C2: CGP Curated Gene Sets (v6.0) 2.073E-3 3.690E-2
2.594E-1
1.000E0
 1 8
36 16115903-TableS1 Human Breast Rouzier05 298genes 4classes GeneSigDB 2.120E-3 3.690E-2
2.594E-1
1.000E0
 2 280
37 M17183 Set 'Oct4 targets': genes upregulated and identified by ChIP on chip as OCT4 [GeneID=5460] transcription factor targets in human embryonic stem cells. MSigDB C2: CGP Curated Gene Sets (v6.0) 2.272E-3 3.690E-2
2.594E-1
1.000E0
 2 290
38 21131918-Table1 Human Ovarian Kalloger10 9genes IHCpanel GeneSigDB 2.332E-3 3.690E-2
2.594E-1
1.000E0
 1 9
39 M12486 Genes whose expression is coregulated with that of RUNX1 [GeneID=861] in hematopoietic stem cells (HSC). MSigDB C2: CGP Curated Gene Sets (v6.0) 2.332E-3 3.690E-2
2.594E-1
1.000E0
 1 9
40 18397756-TableS3b Mouse StemCell Haug08 11genes GeneSigDB 2.332E-3 3.690E-2
2.594E-1
1.000E0
 1 9
41 17823238-TableS7b Human EmbryonicStemCell Soh07 27genes B GeneSigDB 2.591E-3 4.000E-2
2.811E-1
1.000E0
 1 10
42 17636412-table1 Human Prostate Biancolella07 11genes GeneSigDB 2.849E-3 4.071E-2
2.862E-1
1.000E0
 1 11
43 16266989-Table2 Human Breast Hodgson05 12genes GeneSigDB 2.849E-3 4.071E-2
2.862E-1
1.000E0
 1 11
44 M16845 Amplification hot spot 12: colocolized fragile sites and cancer genes in the 17q11.1-q21; 17q25 region. MSigDB C2: CGP Curated Gene Sets (v6.0) 2.849E-3 4.071E-2
2.862E-1
1.000E0
 1 11
45 M854 Genes whose expression profile is specific to Cluster III of urothelial cell carcinoma (UCC) tumors. MSigDB C2: CGP Curated Gene Sets (v6.0) 2.894E-3 4.071E-2
2.862E-1
1.000E0
 2 328
46 17899371-GeneTable4 Human Breast Lauss08 374genes GeneSigDB 3.551E-3 4.553E-2
3.200E-1
1.000E0
 2 364
47 M1807 Genes important for ovulation, based on mouse models with female fertility defects. MSigDB C2: CGP Curated Gene Sets (v6.0) 3.625E-3 4.553E-2
3.200E-1
1.000E0
 1 14
48 20158880-ST-d Human Breast Grinchuk10 17genes KolmogorovSmirnovTestUppsala GeneSigDB 3.625E-3 4.553E-2
3.200E-1
1.000E0
 1 14
49 15901920-Table3 Rat Testicular Naciff05 23genes GeneSigDB 3.625E-3 4.553E-2
3.200E-1
1.000E0
 1 14
50 20158880-ST-c Human Breast Grinchuk10 17genes KolmogorovSmirnovTestStockholm GeneSigDB 3.625E-3 4.553E-2
3.200E-1
1.000E0
 1 14
Show 45 more annotations

14: Coexpression Atlas [Display Chart] 6 input genes in category / 562 annotations before applied cutoff / 21829 genes in category

No results to display

15: Computational [Display Chart] 4 input genes in category / 34 annotations before applied cutoff / 10037 genes in category

No results to display

16: MicroRNA [Display Chart] 6 input genes in category / 238 annotations before applied cutoff / 72241 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 hsa-miR-4281:mirSVR lowEffct hsa-miR-4281:mirSVR nonconserved lowEffect-0.1-0.5 MicroRNA.org 3.584E-6 8.530E-4 5.162E-3 8.530E-4 3 410
2 hsa-miR-508-5p:PITA hsa-miR-508-5p:PITA TOP PITA 1.091E-4 1.298E-2
7.855E-2
 2.596E-2 2 196
3 hsa-miR-410:PITA hsa-miR-410:PITA TOP PITA 3.747E-4 2.676E-2
1.620E-1
8.919E-2
 2 364
4 hsa-miR-4292:mirSVR highEffct hsa-miR-4292:mirSVR nonconserved highEffect-0.5 MicroRNA.org 4.498E-4 2.676E-2
1.620E-1
1.071E-1
 2 399
5 hsa-miR-641:PITA hsa-miR-641:PITA TOP PITA 6.764E-4 3.220E-2
1.948E-1
1.610E-1
 2 490
6 AACGGTT,MIR-451:MSigDB AACGGTT,MIR-451:MSigDB MSigDB 9.133E-4 3.227E-2
1.953E-1
2.174E-1
 1 11
7 hsa-miR-4790-5p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 1.328E-3 3.227E-2
1.953E-1
3.161E-1
 1 16
8 hsa-miR-4315:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 1.577E-3 3.227E-2
1.953E-1
3.753E-1
 1 19
9 hsa-miR-451a:TargetScan hsa-miR-451a TargetScan 1.577E-3 3.227E-2
1.953E-1
3.753E-1
 1 19
10 hsa-miR-323b-5p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 2.158E-3 3.227E-2
1.953E-1
5.135E-1
 1 26
11 CACGTTT,MIR-302A:MSigDB CACGTTT,MIR-302A:MSigDB MSigDB 2.406E-3 3.227E-2
1.953E-1
5.727E-1
 1 29
12 hsa-miR-451a:Functional MTI Functional MTI miRTarbase 2.572E-3 3.227E-2
1.953E-1
6.121E-1
 1 31
13 hsa-miR-1298:PITA hsa-miR-1298:PITA TOP PITA 2.821E-3 3.227E-2
1.953E-1
6.713E-1
 1 34
14 CTCTATG,MIR-368:MSigDB CTCTATG,MIR-368:MSigDB MSigDB 3.152E-3 3.227E-2
1.953E-1
7.502E-1
 1 38
15 hsa-miR-451:PITA hsa-miR-451:PITA TOP PITA 3.649E-3 3.227E-2
1.953E-1
8.685E-1
 1 44
16 GTCAGGA,MIR-378:MSigDB GTCAGGA,MIR-378:MSigDB MSigDB 4.146E-3 3.227E-2
1.953E-1
9.867E-1
 1 50
17 hsa-miR-5187-3p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 4.146E-3 3.227E-2
1.953E-1
9.867E-1
 1 50
18 hsa-miR-4427:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 4.394E-3 3.227E-2
1.953E-1
1.000E0
 1 53
19 hsa-miR-4506:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 4.394E-3 3.227E-2
1.953E-1
1.000E0
 1 53
20 hsa-miR-193a-5p:Functional MTI Functional MTI miRTarbase 4.725E-3 3.227E-2
1.953E-1
1.000E0
 1 57
21 hsa-miR-126-3p:Functional MTI Functional MTI miRTarbase 4.725E-3 3.227E-2
1.953E-1
1.000E0
 1 57
22 hsa-miR-888-3p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 5.304E-3 3.227E-2
1.953E-1
1.000E0
 1 64
23 hsa-miR-3127-5p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 5.304E-3 3.227E-2
1.953E-1
1.000E0
 1 64
24 hsa-miR-301b-5p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 5.387E-3 3.227E-2
1.953E-1
1.000E0
 1 65
25 hsa-miR-2116-5p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 5.469E-3 3.227E-2
1.953E-1
1.000E0
 1 66
26 hsa-miR-6730-3p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 5.635E-3 3.227E-2
1.953E-1
1.000E0
 1 68
27 hsa-miR-155-3p:Functional MTI Functional MTI miRTarbase 5.635E-3 3.227E-2
1.953E-1
1.000E0
 1 68
28 hsa-miR-301a-5p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 5.635E-3 3.227E-2
1.953E-1
1.000E0
 1 68
29 ACAACTT,MIR-382:MSigDB ACAACTT,MIR-382:MSigDB MSigDB 5.717E-3 3.227E-2
1.953E-1
1.000E0
 1 69
30 hsa-miR-4680-3p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 5.800E-3 3.227E-2
1.953E-1
1.000E0
 1 70
31 hsa-miR-4326:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 5.965E-3 3.227E-2
1.953E-1
1.000E0
 1 72
32 hsa-miR-7156-5p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 6.544E-3 3.227E-2
1.953E-1
1.000E0
 1 79
33 hsa-miR-217:Functional MTI Functional MTI miRTarbase 6.626E-3 3.227E-2
1.953E-1
1.000E0
 1 80
34 hsa-miR-4273:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 6.626E-3 3.227E-2
1.953E-1
1.000E0
 1 80
35 hsa-miR-6739-3p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 6.791E-3 3.227E-2
1.953E-1
1.000E0
 1 82
36 hsa-miR-4790-3p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 6.957E-3 3.227E-2
1.953E-1
1.000E0
 1 84
37 hsa-miR-6072:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 6.957E-3 3.227E-2
1.953E-1
1.000E0
 1 84
38 hsa-miR-645:PITA hsa-miR-645:PITA TOP PITA 7.039E-3 3.227E-2
1.953E-1
1.000E0
 1 85
39 hsa-miR-6891-3p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 7.039E-3 3.227E-2
1.953E-1
1.000E0
 1 85
40 hsa-miR-3921:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 7.122E-3 3.227E-2
1.953E-1
1.000E0
 1 86
41 hsa-miR-22-5p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 7.204E-3 3.227E-2
1.953E-1
1.000E0
 1 87
42 hsa-miR-4653-5p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 7.204E-3 3.227E-2
1.953E-1
1.000E0
 1 87
43 hsa-miR-4464:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 7.369E-3 3.227E-2
1.953E-1
1.000E0
 1 89
44 GTTATAT,MIR-410:MSigDB GTTATAT,MIR-410:MSigDB MSigDB 7.452E-3 3.227E-2
1.953E-1
1.000E0
 1 90
45 hsa-miR-4748:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 7.452E-3 3.227E-2
1.953E-1
1.000E0
 1 90
46 hsa-miR-939:PITA hsa-miR-939:PITA TOP PITA 7.452E-3 3.227E-2
1.953E-1
1.000E0
 1 90
47 hsa-miR-4677-5p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 7.535E-3 3.227E-2
1.953E-1
1.000E0
 1 91
48 hsa-miR-299-3p:TargetScan hsa-miR-299-3p TargetScan 7.782E-3 3.227E-2
1.953E-1
1.000E0
 1 94
49 hsa-miR-7845-5p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 8.112E-3 3.227E-2
1.953E-1
1.000E0
 1 98
50 hsa-miR-196b*:mirSVR highEffct hsa-miR-196b*:mirSVR nonconserved highEffect-0.5 MicroRNA.org 8.112E-3 3.227E-2
1.953E-1
1.000E0
 1 98
Show 45 more annotations

17: Drug [Display Chart] 6 input genes in category / 2556 annotations before applied cutoff / 22841 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 CID011228183 ABT-737 Stitch 1.725E-7 4.409E-4 3.714E-3 4.409E-4 2 3
2 CID000447959 1pxm Stitch 7.905E-7 7.513E-4 6.329E-3 2.021E-3 3 79
3 CID000069537 1H,1H,2H,2H-perfluorooctan-1-ol Stitch 1.207E-6 7.513E-4 6.329E-3 3.085E-3 2 7
4 CID000069619 8:2 FTOH Stitch 1.207E-6 7.513E-4 6.329E-3 3.085E-3 2 7
5 ctd:C508406 1H,1H,2H,2H-perfluorooctan-1-ol CTD 1.609E-6 7.513E-4 6.329E-3 4.113E-3 2 8
6 CID000007115 p-terphenyl Stitch 1.764E-6 7.513E-4 6.329E-3 4.508E-3 3 103
7 CID000002375 bicalutamide Stitch 3.162E-6 1.060E-3 8.926E-3 8.082E-3 3 125
8 CID000447961 2C5P Stitch 3.317E-6 1.060E-3 8.926E-3 8.478E-3 3 127
9 ctd:C033729 1H,1H,2H,2H-perfluorodecanol CTD 4.480E-6 1.272E-3 1.072E-2 1.145E-2 2 13
10 ctd:C035988 procymidone CTD 6.157E-6 1.574E-3 1.326E-2 1.574E-2 3 156
11 CID000481402 AC1LA4KK Stitch 7.807E-6 1.814E-3 1.528E-2 1.995E-2 2 17
12 ctd:D008043 Linseed Oil CTD 9.814E-6 1.955E-3 1.646E-2 2.508E-2 2 19
13 CID000010603 hematoxilina Stitch 9.941E-6 1.955E-3 1.646E-2 2.541E-2 3 183
14 CID000009380 1,2-dimethylhydrazine dihydrochloride Stitch 1.090E-5 1.991E-3 1.677E-2 2.787E-2 2 20
15 CID000108092 tesmilifene Stitch 1.205E-5 2.053E-3 1.730E-2 3.080E-2 2 21
16 CID000010089 phenadoxone Stitch 1.325E-5 2.117E-3 1.783E-2 3.387E-2 2 22
17 CID004369534 DB07570 Stitch 2.013E-5 3.026E-3 2.549E-2
5.144E-2
 2 27
18 CID006432721 Tl-I Stitch 2.327E-5 3.305E-3 2.784E-2
5.949E-2
 2 29
19 CID000005377 AC1L1K7W Stitch 3.214E-5 4.157E-3 3.502E-2
8.215E-2
 2 34
20 ctd:C013598 methoxyacetic acid CTD 3.253E-5 4.157E-3 3.502E-2
8.315E-2
 3 272
21 CID000448658 Id-5 Stitch 3.608E-5 4.392E-3 3.700E-2
9.223E-2
 2 36
22 CID000002187 anastrozole Stitch 3.814E-5 4.431E-3 3.733E-2
9.749E-2
 2 37
23 CID000448668 wiskostatin Stitch 4.243E-5 4.715E-3 3.972E-2
1.084E-1
 2 39
24 CID004629338 AC1NDP1R Stitch 4.928E-5 5.248E-3 4.421E-2
1.260E-1
 2 42
25 CID000060198 exemestane Stitch 5.168E-5 5.284E-3 4.451E-2
1.321E-1
 2 43
26 CID000013930 heptachlor epoxide Stitch 5.921E-5 5.821E-3 4.903E-2
1.513E-1
 2 46
27 ctd:D015251 Epirubicin CTD 6.184E-5 5.854E-3 4.931E-2
1.581E-1
 2 47
28 CID000013089 o,p'-DDT Stitch 6.726E-5 6.140E-3
5.172E-2
1.719E-1
 2 49
29 CID000508110 AC1LA6KT Stitch 7.290E-5 6.425E-3
5.412E-2
1.863E-1
 2 51
30 CID000096840 BB D Stitch 8.179E-5 6.744E-3
5.681E-2
2.091E-1
 2 54
31 ctd:C025463 sulindac sulfone CTD 8.179E-5 6.744E-3
5.681E-2
2.091E-1
 2 54
32 ctd:C112765 tanespimycin CTD 8.800E-5 7.029E-3
5.921E-2
2.249E-1
 2 56
33 CID000128831 CK17 Stitch 9.119E-5 7.063E-3
5.950E-2
2.331E-1
 2 57
34 ctd:C000621033 napabucasin CTD 1.151E-4 8.652E-3
7.288E-2
2.942E-1
 2 64
35 CID004635324 AC1NE222 Stitch 1.187E-4 8.671E-3
7.304E-2
3.035E-1
 2 65
36 CID000004048 AC1Q6OH3 Stitch 1.224E-4 8.693E-3
7.322E-2
3.129E-1
 2 66
37 CID000003902 letrozole Stitch 1.262E-4 8.717E-3
7.343E-2
3.225E-1
 2 67
38 CID005288598 1wvj Stitch 1.339E-4 8.720E-3
7.345E-2
3.421E-1
 2 69
39 CID000060843 pemetrexed Stitch 1.458E-4 8.720E-3
7.345E-2
3.726E-1
 2 72
40 CID006437840 hydroxyethylretinamide Stitch 1.499E-4 8.720E-3
7.345E-2
3.831E-1
 2 73
41 CID000200890 P-29 Stitch 1.582E-4 8.720E-3
7.345E-2
4.044E-1
 2 75
42 ctd:D000726 Androgen Antagonists CTD 1.582E-4 8.720E-3
7.345E-2
4.044E-1
 2 75
43 CID000448538 AC1L9M2J Stitch 1.625E-4 8.720E-3
7.345E-2
4.153E-1
 2 76
44 CID000001642 AC1L1BWR Stitch 1.625E-4 8.720E-3
7.345E-2
4.153E-1
 2 76
45 CID000005410 NSC98537 Stitch 1.685E-4 8.720E-3
7.345E-2
4.306E-1
 3 473
46 CID000008420 2-naphthalenesulfonate Stitch 2.382E-4 8.720E-3
7.345E-2
6.088E-1
 2 92
47 CID000093138 AC1L3PKS Stitch 2.594E-4 8.720E-3
7.345E-2
6.629E-1
 2 96
48 CID009869358 CHEMBL372390 Stitch 2.627E-4 8.720E-3
7.345E-2
6.714E-1
 1 1
49 CID009820510 CHEMBL227408 Stitch 2.627E-4 8.720E-3
7.345E-2
6.714E-1
 1 1
50 ctd:D002486 Centchroman CTD 2.627E-4 8.720E-3
7.345E-2
6.714E-1
 1 1
Show 45 more annotations

18: Disease [Display Chart] 6 input genes in category / 639 annotations before applied cutoff / 16205 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 C0813147 Stage I Endometrial Carcinoma DisGeNET BeFree 3.196E-6 6.387E-4 4.495E-3 2.042E-3 2 8
2 C1706827 Carcinoma of apocrine gland DisGeNET BeFree 3.196E-6 6.387E-4 4.495E-3 2.042E-3 2 8
3 C3146271 Stage III Breast Cancer AJCC v7 DisGeNET BeFree 4.108E-6 6.387E-4 4.495E-3 2.625E-3 2 9
4 C0278487 Stage III Breast Cancer AJCC v6 DisGeNET BeFree 4.108E-6 6.387E-4 4.495E-3 2.625E-3 2 9
5 C0278802 Recurrent Endometrial Cancer DisGeNET BeFree 5.134E-6 6.387E-4 4.495E-3 3.281E-3 2 10
6 C3642345 Luminal A Breast Carcinoma DisGeNET BeFree 5.997E-6 6.387E-4 4.495E-3 3.832E-3 3 110
7 C1096616 contralateral breast cancer DisGeNET BeFree 8.895E-6 8.120E-4 5.715E-3 5.684E-3 2 13
8 C3642347 Basal-Like Breast Carcinoma DisGeNET BeFree 1.550E-5 1.100E-3 7.745E-3 9.904E-3 2 17
9 C0302180 Condyloma DisGeNET BeFree 1.550E-5 1.100E-3 7.745E-3 9.904E-3 2 17
10 C1336076 Sporadic Breast Carcinoma DisGeNET BeFree 1.919E-5 1.150E-3 8.096E-3 1.226E-2 3 162
11 C0205645 Adenocarcinoma, Tubular DisGeNET BeFree 2.164E-5 1.150E-3 8.096E-3 1.383E-2 2 20
12 C0085750 Adenosis of Breast DisGeNET BeFree 2.164E-5 1.150E-3 8.096E-3 1.383E-2 2 20
13 C0011848 Diabetes Insipidus DisGeNET Curated 2.630E-5 1.150E-3 8.096E-3 1.681E-2 2 22
14 C3549742 Breast cancer, lobular DisGeNET BeFree 2.630E-5 1.150E-3 8.096E-3 1.681E-2 2 22
15 C0027831 Neurofibromatosis 1 DisGeNET Curated 2.764E-5 1.150E-3 8.096E-3 1.766E-2 3 183
16 C0281267 bilateral breast cancer DisGeNET BeFree 2.881E-5 1.150E-3 8.096E-3 1.841E-2 2 23
17 C0334381 Non-infiltrating lobular carcinoma DisGeNET BeFree 3.142E-5 1.181E-3 8.312E-3 2.008E-2 2 24
18 C0279563 Lobular carcinoma in situ of breast DisGeNET BeFree 3.698E-5 1.313E-3 9.240E-3 2.363E-2 2 26
19 C0598935 Tumor Initiation DisGeNET BeFree 5.831E-5 1.918E-3 1.350E-2 3.726E-2 3 235
20 C1384494 Metastatic Carcinoma DisGeNET BeFree 6.002E-5 1.918E-3 1.350E-2 3.835E-2 2 33
21 C0206685 Acinar Cell Carcinoma DisGeNET BeFree 6.376E-5 1.940E-3 1.365E-2 4.074E-2 2 34
22 C0221228 Comedone DisGeNET BeFree 7.565E-5 2.197E-3 1.546E-2 4.834E-2 2 37
23 C1335475 Primary Carcinoma DisGeNET BeFree 9.772E-5 2.715E-3 1.911E-2
6.244E-2
 2 42
24 C0242787 Malignant neoplasm of male breast DisGeNET BeFree 1.025E-4 2.728E-3 1.920E-2
6.548E-2
 2 43
25 C3669246 Mammary adenocarcinoma DisGeNET BeFree 1.073E-4 2.743E-3 1.931E-2
6.859E-2
 2 44
26 C1332347 Atypical Ductal Breast Hyperplasia DisGeNET BeFree 1.174E-4 2.885E-3 2.031E-2
7.501E-2
 2 46
27 C0007104 Female Breast Carcinoma DisGeNET BeFree 1.389E-4 3.060E-3 2.153E-2
8.873E-2
 2 50
28 C0235653 Malignant neoplasm of female breast DisGeNET BeFree 1.389E-4 3.060E-3 2.153E-2
8.873E-2
 2 50
29 C0677776 Hereditary Breast and Ovarian Cancer Syndrome DisGeNET Curated 1.389E-4 3.060E-3 2.153E-2
8.873E-2
 2 50
30 C0279565 Invasive Lobular Breast Carcinoma DisGeNET BeFree 1.503E-4 3.200E-3 2.252E-2
9.601E-2
 2 52
31 C0238033 Carcinoma of Male Breast DisGeNET BeFree 1.807E-4 3.479E-3 2.449E-2
1.155E-1
 2 57
32 C1512127 HER2 gene amplification DisGeNET BeFree 1.807E-4 3.479E-3 2.449E-2
1.155E-1
 2 57
33 C0027708 Nephroblastoma DisGeNET Curated 1.824E-4 3.479E-3 2.449E-2
1.166E-1
 3 345
34 C0206650 Fibroadenoma DisGeNET Curated 1.871E-4 3.479E-3 2.449E-2
1.196E-1
 2 58
35 C0153567 Uterine Cancer DisGeNET BeFree 1.937E-4 3.479E-3 2.449E-2
1.237E-1
 2 59
36 C1569637 Adenocarcinoma, Endometrioid DisGeNET BeFree 2.071E-4 3.479E-3 2.449E-2
1.323E-1
 2 61
37 C0279672 Cervical Adenocarcinoma DisGeNET BeFree 2.352E-4 3.479E-3 2.449E-2
1.503E-1
 2 65
38 C0853879 Invasive carcinoma of breast DisGeNET BeFree 2.523E-4 3.479E-3 2.449E-2
1.612E-1
 3 385
39 C0278488 Carcinoma breast stage IV DisGeNET BeFree 2.621E-4 3.479E-3 2.449E-2
1.675E-1
 3 390
40 C0016034 Breast Fibrocystic Disease DisGeNET BeFree 3.217E-4 3.479E-3 2.449E-2
2.055E-1
 2 76
41 C2986665 Early-Stage Breast Carcinoma DisGeNET BeFree 3.217E-4 3.479E-3 2.449E-2
2.055E-1
 2 76
42 C3642346 Luminal B Breast Carcinoma DisGeNET BeFree 3.476E-4 3.479E-3 2.449E-2
2.221E-1
 2 79
43 C0008487 Chordoma DisGeNET Curated 3.476E-4 3.479E-3 2.449E-2
2.221E-1
 2 79
44 C0003886 Arthrogryposis DisGeNET Curated 3.654E-4 3.479E-3 2.449E-2
2.335E-1
 2 81
45 cv:C3150659 Breast-ovarian cancer, familial 3 Clinical Variations 3.703E-4 3.479E-3 2.449E-2
2.366E-1
 1 1
46 C1527375 Cystic Breast Disease DisGeNET BeFree 3.703E-4 3.479E-3 2.449E-2
2.366E-1
 1 1
47 C1514507 Prostate Basal Cell Carcinoma DisGeNET BeFree 3.703E-4 3.479E-3 2.449E-2
2.366E-1
 1 1
48 C0279633 intestinal adenocarcinoma of the stomach DisGeNET BeFree 3.703E-4 3.479E-3 2.449E-2
2.366E-1
 1 1
49 C1142347 Stage IV Esophageal Adenocarcinoma DisGeNET BeFree 3.703E-4 3.479E-3 2.449E-2
2.366E-1
 1 1
50 C2930879 Cerebellar degeneration, subacute DisGeNET BeFree 3.703E-4 3.479E-3 2.449E-2
2.366E-1
 1 1
Show 45 more annotations